Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation

References

• Mehta J, Powles R, Singhal S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499–506
   PubMed Web of Science ®Google Scholar
• Barrett A J, Ringden O, Zhang M J, et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323–3327
   PubMed Web of Science ®Google Scholar
• Ringden O, Nilsson B. Death by graft-versus-host disease associated with HLA-mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39–44
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Piaggio G, Podesta M, et al. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 221–226
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996; 18: 741–746
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Read E, Cottler-Fox M, et al. CD34 + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229
   PubMed Web of Science ®Google Scholar
• Sierra J, Storer B, Hansen J A, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose. Blood 1997; 89: 4226–4235
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Treleaven J, et al. Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. Blood 1997; 90: 3808–3810
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Treleaven J, et al. A low CD34 + cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34 + cells/kg be considered the minimum threshold?. Bone Marrow Transplant 2000; 26: 489–496
   PubMed Web of Science ®Google Scholar
• Davies S M, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 2000; 96: 4096–4102
   PubMed Web of Science ®Google Scholar
• Cornelissen J J, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572–1577
   PubMed Web of Science ®Google Scholar
• Dominietto A, Lamparelli A, Raiola A M, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100: 3930–3934
   PubMed Web of Science ®Google Scholar
• Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237
   PubMed Web of Science ®Google Scholar
• Singhal S, Powles R, Kulkarni S, et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs. blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 501–505
   PubMed Web of Science ®Google Scholar
• Körbling M, Przepiorka D, Huh Y O, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659–1665
   PubMed Web of Science ®Google Scholar
• Bensinger W I, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794–2800
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Smith T L, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465–1470
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700
   PubMed Web of Science ®Google Scholar
• Zaucha J M, Gooley T, Bensinger W I, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221–3227
   PubMed Web of Science ®Google Scholar
• Cilley J, Rihn C, Monreal J, et al. Ideal or actual body weight to calculate CD34 + cell doses for allogeneic hematopoietic stem cell transplantation?. Bone Marrow Transplant 2004; 33: 161–164
   PubMed Web of Science ®Google Scholar
• Singhal S, Gordon L I, Tallman M S, et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 553–557, (Erratum in: Bone Marrow Transplant 2006;37:1067)
   PubMed Web of Science ®Google Scholar
• Singhal S, Gordon L, Meagher R, et al. The CD34 + cell dose, even in an ‘acceptable’ range, affects outcome of allogeneic blood stem cell transplantation. Blood (Suppl) 2004; 104: 1153, (Abstract)
   Google Scholar
• Ringdén O, Barrett A J, Zhang M J, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003; 121: 874–885
   PubMed Web of Science ®Google Scholar
• Nakamura R, Auayporn N, Smith D D, et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34 + cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008; 14: 449–457
   PubMed Web of Science ®Google Scholar
• Körbling M, Katz R L, Khanna A, et al. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 2002; 346: 738–746
   PubMed Web of Science ®Google Scholar